COOPER COMPANIES, INC.

The Cooper Companies, Inc. reported a significant net loss of $77.9 million for the three months ended April 30, 2026, a sharp decline from a net income of $87.7 million in the same period last year. While net sales saw an increase to $1,081.5 million for the quarter and $2,105.6 million for the six months, the company was heavily impacted by a $271.6 million litigation expense related to CooperSurgical. This resulted in a substantial operating loss for the CooperSurgical segment and a consolidated net loss for the quarter. The company's total assets grew slightly to $12,482.3 million, but short-term debt saw a significant increase.

The Cooper Companies, Inc. announced its fiscal second quarter 2026 results, reporting a revenue increase of 8% to $1.082 billion. However, GAAP diluted EPS was negatively impacted by a significant $271.6 million litigation-related charge stemming from a CooperSurgical product recall, resulting in a GAAP loss per share of $(0.40). Non-GAAP diluted EPS showed strong growth, up 26% to $1.21. The company also updated its full-year financial guidance.

CooperCompanies announced its fiscal second quarter 2026 results, with revenue reaching $1.082 billion, an 8% increase year-over-year. While non-GAAP diluted EPS saw a significant 26% increase to $1.21, GAAP diluted EPS was $(0.40) due to a substantial litigation-related charge of $271.6 million stemming from a product recall at CooperSurgical. The company also updated its fiscal year 2026 financial guidance, projecting total revenue between $4.285 billion and $4.321 billion and non-GAAP diluted EPS between $4.58 and $4.66.

CooperCompanies announced the appointment of Paul Keel as an independent director to its Board of Directors, effective July 1, 2026. The Board also approved an increase in its size from nine to ten directors. Mr. Keel, who currently serves as President and CEO of Envista Holdings Corporation, will also join the Audit Committee. His extensive experience in the medical device sector and global operations is expected to be a significant asset.

CooperCompanies announced the appointment of Paul Keel as an independent director to its Board of Directors, effective July 1, 2026. Mr. Keel will also serve on the Audit Committee. He brings extensive experience as a CEO in the medical device sector, having led Envista Holdings Corporation and Smiths Group plc, and held various leadership roles at 3M. The company expects his expertise to be a significant asset in executing its strategy and creating long-term value for stakeholders.

CooperCompanies announced it will release its second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. Investors can access the call via dial-in or a simultaneous audio webcast.